U.S. Renewable Energy Stock News

NYSE:KODK
NYSE:KODKTech

A Look At Kodak (KODK) Valuation As New Hubble Connected Smart Family Products Are Announced

Eastman Kodak (KODK) is in focus after Hubble Connected unveiled plans for a new line of Kodak licensed smart family products, set to debut at the ABC Kids Expo in Las Vegas. See our latest analysis for Eastman Kodak. The licensing news lands after a mixed stretch in the stock, with the share price down 26.37% over the past 30 days but up 26.34% over 90 days and a 49.31% one year total shareholder return, suggesting momentum has been choppy rather than moving in a single direction. If this...
NYSE:DAN
NYSE:DANAuto Components

Dana (DAN) Discontinued Ops Windfall Tests Bullish Margin Repair Narrative

Dana (DAN) opened Q1 2026 with total revenue of US$1,868 million and a basic EPS loss of US$0.17, giving investors a fresh read on how top line scale is translating into the bottom line. Over the past year, the company has seen quarterly revenue move from US$1,781 million in Q1 2025 to US$1,868 million in Q1 2026. Basic EPS has ranged from a loss of US$1.37 in Q4 2024 to a loss of US$0.35 in Q4 2025 and a loss of US$0.17 in the latest quarter. This progression sets up a story that is focused...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Mirum’s VISTAS Success And What It Could Mean For MIRM Shareholders

Mirum Pharmaceuticals reported positive topline VISTAS Phase 2b results for volixibat in primary sclerosing cholangitis related cholestatic pruritus. The trial showed a robust, clinically meaningful improvement in itch symptoms for PSC patients, who currently have no approved treatment options. Following the data, Mirum has a pre NDA meeting scheduled and plans to file for regulatory approval for volixibat. For investors tracking Mirum Pharmaceuticals, ticker NasdaqGM:MIRM, this update sits...
NYSE:EVR
NYSE:EVRCapital Markets

Evercore’s Standout Quarter And Senior Equities Hire Reshape Growth Outlook

Evercore (NYSE:EVR) reported an exceptional first quarter, delivering the fastest revenue growth among its investment banking peers. The company significantly exceeded analyst expectations for the period. Evercore also strengthened its Equities division with the hire of a highly experienced industry veteran to a senior role. Evercore enters this news cycle with the stock at $333.56 and a 1 year return of 39.7%. Despite this, the share price is down 5.0% year to date, 8.1% over the past...
NYSE:HTGC
NYSE:HTGCCapital Markets

Hercules Capital Leadership Shift Tests Growth Plans And Dividend Coverage

Hercules Capital (NYSE:HTGC) has promoted longtime CFO Seth H. Meyer to President. Andrew Olson, who has experience in private credit, venture capital and prior roles at Hercules, has been appointed as the new CFO. These leadership changes mark a material shift in the company's executive team and could influence how Hercules Capital is run and where it focuses next. Hercules Capital, a lender focused on venture and growth stage companies, is making these leadership moves while its stock...
NYSE:AYI
NYSE:AYIElectrical

Is It Time To Reassess Acuity Brands (AYI) After The Recent Share Price Pullback?

If you have been wondering whether Acuity's current share price reflects its true worth, this article walks through what the numbers are actually saying about the stock. Acuity closed at US$281.63 recently, with the share price down 4.0% over the past week, down 3.8% over the past month, but showing gains of 3.4% over 1 year, 78.3% over 3 years and 61.0% over 5 years. Recent coverage of Acuity has focused on how the stock's longer term gains contrast with its more recent pullback, prompting...
NYSE:CYD
NYSE:CYDMachinery

Is It Too Late To Consider China Yuchai International (CYD) After A 196% One-Year Surge?

For readers considering whether China Yuchai International at around US$50 is still offering value after a strong run, or if the easy gains are behind it, this article breaks down what the current price might be implying about the stock. The stock has posted returns of 8.1% over the past week, 15.6% over the past month, 35.1% year to date and 196.6% over the past year, which has sharpened the focus on both potential upside and changing risk. Recent news coverage has centered on China Yuchai...
NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

A Look At SIGA Technologies (SIGA) Valuation After Weaker First Quarter 2026 Results

First quarter earnings spark fresh look at SIGA Technologies SIGA Technologies (SIGA) has drawn fresh attention after reporting first quarter 2026 results, with revenue of US$6.24 million and a net loss of US$3.45 million, compared with the same period a year earlier. See our latest analysis for SIGA Technologies. The 1-day share price return of 2.11% and 7-day move down 13.12% leave SIGA trading at US$4.17, with the 1-year total shareholder return also down 21.30%, suggesting momentum has...